It was found that the rapamycin derivatives inhibit AKT signaling in primary AML cells both in vitro and in vivo, supporting the therapeutic potential of mTOR inhibition strategies in leukemias and multiple myeloma dissemination and angiogenesis [67, 68]. The gene discussed is AKT1; the disease is plasma cell myeloma.